Compass Therapeutics price target raised to $12 from $10 at Guggenheim

Guggenheim analyst Michael Schmidt raised the firm’s price target on Compass Therapeutics (CMPX) to $12 from $10 and keeps a Buy rating on the shares. Q2 results included “a positive pipeline update and new clinical data,” says the analyst, who notes that management is now officially guiding to announcing the final PFS and OS analysis of the ongoing COMPANION-002 Phase 2/3 trial of tovecimig in second-line and later biliary tract cancer in Q1 of 2026, versus Q4 of 2025 previously. The firm’s raised target reflects the addition of highly probability-of-success-adjusted value for CTX-8371 and incrementally higher conviction on tovecimg, the analyst noted.